Aortic valve disease in diabetes: Molecular mechanisms and novel therapies

Area of Science:

• Cardiovascular Research
• Diabetology
• Pathology

Background:

• Calcific aortic valve disease (CAVD) and diabetes mellitus (DM) are progressive global health burdens, particularly in aging populations.
• Diabetic patients exhibit a higher risk of cardiovascular disorders and accelerated degeneration of bioprosthetic aortic valves compared to non-diabetic individuals.
• Current pharmacological treatments to reverse or slow aortic valve disease progression in diabetes are lacking.

Purpose of the Study:

• To review current basic research on CAVD in the context of diabetes.
• To elucidate the mechanisms underlying diabetes-induced aortic valve disease progression.
• To identify potential biomarkers, therapeutic targets, and novel treatment strategies for CAVD in diabetic patients.

Main Methods:

• Review of existing literature on CAVD and diabetes.
• Analysis of experimental data from diabetic-hyperlipemic hamster models.
• Exploration of cell and molecular alterations in the aortic valve.

Main Results:

• Diabetes induces progressive cell and molecular alterations in the aortic valve, leading to calcification and CAVD.
• Identified potential biomarkers for assessing disease evolution and therapeutic response.
• Highlighted advancements in targeted nanotherapies, tissue engineering, and the role of circulating endothelial progenitor cells.

Conclusions:

• Diabetes significantly exacerbates CAVD, necessitating urgent research into underlying mechanisms.
• Novel biomarkers and therapeutic strategies, including nanotherapies and tissue engineering, show promise for managing CAVD in diabetic patients.
• Further research is critical to develop effective treatments for this complex condition.